US 11,911,456 B2
Multi-CBV vaccine for preventing or treating type I diabetes
Heikki Hyöty, Tampere (FI); Mikael Knip, Helsinki (FI); Olli Laitinen, Tampere (FI); Outi Tolonen, Oulu (FI); Minna Pulkki, Tampere (FI); Sami Oikarinen, Tampere (FI); Hanna-Riikka Honkanen, Hyllykallio (FI); Valérie Lecouturier, Chazay d'Azergues (FR); Jeffrey Almond, Dardilly (FR); and Malin Flodström-Tullberg, Nykoping (SE)
Assigned to Vactech Oy, Tampere (FI)
Filed by Vactech Oy, Tampere (FI)
Filed on Apr. 7, 2021, as Appl. No. 17/224,430.
Application 17/224,430 is a continuation of application No. 16/995,439, filed on Aug. 17, 2020, granted, now 11,633,468.
Application 16/995,439 is a continuation of application No. 16/265,681, filed on Feb. 1, 2019, granted, now 10,780,157, issued on Sep. 22, 2020.
Application 16/265,681 is a continuation of application No. 15/465,854, filed on Mar. 22, 2017, granted, now 10,258,685, issued on Apr. 16, 2019.
Application 15/465,854 is a continuation of application No. 14/352,585, abandoned, previously published as PCT/EP2012/070653, filed on Oct. 18, 2012.
Claims priority of application No. 11306344 (EP), filed on Oct. 18, 2011.
Prior Publication US 2021/0220465 A1, Jul. 22, 2021
Int. Cl. A61K 39/12 (2006.01); A61K 39/125 (2006.01); C07K 16/10 (2006.01); A61K 39/13 (2006.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/125 (2013.01) [A61K 39/12 (2013.01); A61K 39/13 (2013.01); A61K 39/39 (2013.01); C07K 16/1009 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55 (2013.01); A61K 2039/58 (2013.01); C12N 2770/32334 (2013.01)] 21 Claims
 
1. A method of inducing an immune response to coxsackie B virus (CBV) in a pregnant woman, the method comprising administering to the pregnant woman an effective amount of a composition comprising:
a) a nucleic acid encoding a protein or peptide comprising a viral antigenic epitope of CBV1 and a nucleic acid encoding a protein or peptide comprising a viral antigenic epitope of CBV2; and
b) at least one nucleic acid selected from a nucleic acid encoding a protein or peptide comprising a viral antigenic epitope of CBV3, a nucleic acid encoding a protein or peptide comprising a viral antigenic epitope of CBV4, and a nucleic acid encoding a protein or peptide comprising a viral antigenic epitope of CBV5, wherein the composition does not include a nucleic acid encoding a protein or peptide comprising a viral antigenic epitope of CBV6,
wherein said administering induces an immune response to CBV in the pregnant woman.